{
  "identifier": "FOX2lb0F",
  "argumentId": "cmr5cb7af000kg1e2n4796y2b",
  "permalink": "https://www.isonomia.app/a/FOX2lb0F",
  "version": 1,
  "contentHash": "sha256:d1f8a1cdb953bac046482a402fccf61f7934a87f04db62a2b78ff66ab0a80553",
  "immutablePermalink": "https://www.isonomia.app/a/FOX2lb0F@d1f8a1cdb953bac046482a402fccf61f7934a87f04db62a2b78ff66ab0a80553",
  "isoId": "iso:argument:FOX2lb0F",
  "isoUrl": "https://www.isonomia.app/iso/argument/FOX2lb0F",
  "doi": null,
  "retrievedAt": "2026-07-16T18:29:24.569Z",
  "createdAt": "2026-07-03T19:42:22.117Z",
  "updatedAt": "2026-07-03T19:42:22.117Z",
  "conclusion": {
    "claimId": "cmr5cb1p50002g1e2mjkry0fg",
    "moid": "d63433f5dc2380911429b644a5d6b8e34b01feccfdb143ebb66877e52736efd9",
    "text": "For adults with obesity and established cardiovascular disease, long-term (up to ~4 years) GLP-1 receptor agonist therapy is net-beneficial and acceptably safe: its cardiovascular and all-cause mortality benefits outweigh its documented harms, provided lean-mass loss is monitored and the lack of evidence beyond ~4 years is acknowledged."
  },
  "premises": [
    {
      "claimId": "cmr5cb2dy0004g1e2khpmfr1f",
      "moid": "a6403777ad00251b19505c95c1e7cfbbae7f0819d6c88fe05fe5d2fee9e5ce8a",
      "text": "Across meta-analyses of GLP-1 receptor agonist trials, major adverse cardiovascular events are reduced by roughly 12–20% with concordant reductions in cardiovascular and all-cause mortality, and the cardiovascular benefit holds independently of diabetes status.",
      "isImplicit": false
    },
    {
      "claimId": "cmr5cb2up0006g1e2t18ngvvx",
      "moid": "2085a3ff6af08933229cc05d8da1b19c788e1d24b994d7389c6c7410afa1ab5d",
      "text": "The most consistently documented long-term harm is loss of lean/muscle mass — up to roughly 40% of total weight lost can be fat-free mass — raising sarcopenia risk especially in older adults; however this is measurable and partly mitigable with resistance exercise and adequate protein rather than a contraindication.",
      "isImplicit": false
    },
    {
      "claimId": "cmr5cb2ur0009g1e2d7tni6j2",
      "moid": "0556f2435074361146313cba4fa7ed59c0e6fed007017137283abfbaf18e543a",
      "text": "In the SELECT randomized controlled trial — 17,604 adults with obesity and established cardiovascular disease but no diabetes, followed for a mean of ~40 months — once-weekly semaglutide reduced major adverse cardiovascular events (CV death, non-fatal MI, non-fatal stroke) by 20% versus placebo, with concordant reductions in renal outcomes and progression to diabetes.",
      "isImplicit": false
    },
    {
      "claimId": "cmr5cb2ur000ag1e29l0ymd3x",
      "moid": "59022fce832d58171d6cbb05b2f87ed302610d56af11a472c83aee638143e1a0",
      "text": "The most feared serious long-term harms — medullary/thyroid C-cell cancer, pancreatic cancer, and other obesity-related cancers — have not shown statistically significant elevation in pooled randomized and cohort data to date, though absolute event counts are small and dedicated cancer-outcome studies beyond ~2-4 years are still lacking.",
      "isImplicit": false
    },
    {
      "claimId": "cmr5cb2uw000cg1e2zh91ykay",
      "moid": "6214751c3b5714e9952dad159f6255a841a18524688b7559b49fad440ce1e54a",
      "text": "Evidence beyond roughly four years, and in younger or low-cardiovascular-risk populations, remains thin, and at least one meta-analysis reports an unresolved pancreatitis signal (RR ~1.44) that attenuates after adjustment — so the favorable balance is established for high-cardiovascular-risk adults over a multi-year horizon, not proven for indefinite use across all populations.",
      "isImplicit": false
    }
  ],
  "scheme": {
    "id": "cmghcuqw50009zq6mungs49z2",
    "key": "practical_reasoning",
    "name": "Practical Reasoning (Goal→Means→Ought)",
    "title": null,
    "canonicalKey": "practical_reasoning",
    "behaviourFingerprint": "5bfb2b53d62a431f4de84c07d392f93b86e972d972ec9b8a2a2e0b9327a0c4e4",
    "catalogueHealth": {
      "isArgumentPattern": true,
      "isDialogueMeta": false,
      "isTestPlaceholder": false,
      "duplicateOf": null,
      "canonicalKey": "practical_reasoning",
      "clusterTagMissing": false,
      "fingerprintMaterialised": true
    }
  },
  "evidence": [
    {
      "evidenceId": "cmr5cb3jm000dg1e2fmno89fx",
      "uri": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11544414/",
      "title": "SELECT: semaglutide and cardiovascular outcomes in obesity without diabetes",
      "citation": "In 17,604 adults with obesity and established CVD (no diabetes), over a mean ~40 months semaglutide reduced the composite of CV death, non-fatal MI or non-fatal stroke by 20% versus placebo — the largest and longest randomized dataset bearing on long-term GLP-1 safety.",
      "contentSha256": "sha256:5d0aab2ee66d76126abe487e7bb6763f1e360a031b4eeb27bca5b80979e1ed9f",
      "archivedUrl": "https://web.archive.org/web/20260703194225/https://pmc.ncbi.nlm.nih.gov/articles/PMC11544414/",
      "archivedAt": "2026-07-03T19:42:56.268Z"
    }
  ],
  "structuredCitations": [
    {
      "id": "cmr5cb3jm000dg1e2fmno89fx",
      "title": "SELECT: semaglutide and cardiovascular outcomes in obesity without diabetes",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11544414/",
      "doi": null,
      "publisher": "pmc.ncbi.nlm.nih.gov",
      "accessedAt": "2026-07-03T19:42:56.268Z",
      "archivedAt": "2026-07-03T19:42:56.268Z",
      "archivedUrl": "https://web.archive.org/web/20260703194225/https://pmc.ncbi.nlm.nih.gov/articles/PMC11544414/",
      "contentSha256": "sha256:5d0aab2ee66d76126abe487e7bb6763f1e360a031b4eeb27bca5b80979e1ed9f",
      "quote": "In 17,604 adults with obesity and established CVD (no diabetes), over a mean ~40 months semaglutide reduced the composite of CV death, non-fatal MI or non-fatal stroke by 20% versus placebo — the largest and longest randomized dataset bearing on long-term GLP-1 safety.",
      "quoteAnchor": {
        "selector": "In 17,604 adults with obesity and established CVD (no diabetes), over a mean ~40 months semaglutide reduced the composite of CV death, non-fatal MI or non-fatal stroke by 20% versus placebo — the largest and longest randomized dataset bearing on long-term GLP-1 safety.",
        "type": "text-quote"
      }
    }
  ],
  "criticalQuestions": {
    "schemeKey": "practical_reasoning",
    "total": 6,
    "answered": [],
    "partiallyAnswered": [
      {
        "cqKey": "PR.ALTERNATIVES",
        "text": "Is there a better alternative than A to achieve G?",
        "attackKind": "REBUTS",
        "cqStatusId": "cmr5cdhx50010g1e2p0otj7dx",
        "schemeKey": "practical_reasoning",
        "premiseType": "ASSUMPTION",
        "isSchemeRequired": false,
        "inheritedFromParentScheme": false,
        "cqStatusEnum": "PENDING_REVIEW",
        "challenged": false,
        "challengeCount": 0,
        "cqRequiresEvidence": false,
        "cqBurden": "PROPONENT",
        "answerSelfCanonical": true,
        "answerAuthorKind": "AI",
        "status": "pending_review"
      },
      {
        "cqKey": "PR.FEASIBILITY",
        "text": "Is A feasible for the agent (ability, resources, time)?",
        "attackKind": "UNDERMINES",
        "cqStatusId": "cmr5cet94001fg1e2934fd2bd",
        "schemeKey": "practical_reasoning",
        "premiseType": "ASSUMPTION",
        "isSchemeRequired": false,
        "inheritedFromParentScheme": false,
        "cqStatusEnum": "PENDING_REVIEW",
        "challenged": false,
        "challengeCount": 0,
        "cqRequiresEvidence": false,
        "cqBurden": "PROPONENT",
        "answerSelfCanonical": true,
        "answerAuthorKind": "AI",
        "status": "pending_review"
      },
      {
        "cqKey": "PR.GOAL_ACCEPTED",
        "text": "Is the goal/value G explicit and acceptable?",
        "attackKind": "UNDERMINES",
        "cqStatusId": "cmr5cd9ja000qg1e25pw4f7j7",
        "schemeKey": "practical_reasoning",
        "premiseType": "ASSUMPTION",
        "isSchemeRequired": false,
        "inheritedFromParentScheme": false,
        "cqStatusEnum": "PENDING_REVIEW",
        "challenged": false,
        "challengeCount": 0,
        "cqRequiresEvidence": false,
        "cqBurden": "PROPONENT",
        "answerSelfCanonical": true,
        "answerAuthorKind": "AI",
        "status": "pending_review"
      },
      {
        "cqKey": "PR.MEANS_EFFECTIVE",
        "text": "Will doing A actually achieve G in the present context?",
        "attackKind": "UNDERCUTS",
        "cqStatusId": "cmr5cdcka000vg1e2ueiqub23",
        "schemeKey": "practical_reasoning",
        "premiseType": "ORDINARY",
        "isSchemeRequired": true,
        "inheritedFromParentScheme": false,
        "cqStatusEnum": "PENDING_REVIEW",
        "challenged": false,
        "challengeCount": 0,
        "cqRequiresEvidence": false,
        "cqBurden": "PROPONENT",
        "answerSelfCanonical": true,
        "answerAuthorKind": "AI",
        "status": "pending_review"
      },
      {
        "cqKey": "PR.PERMISSIBILITY",
        "text": "Is doing A permissible/appropriate given norms or constraints?",
        "attackKind": "REBUTS",
        "cqStatusId": "cmr5cdv7v001ag1e2ngpj1gqp",
        "schemeKey": "practical_reasoning",
        "premiseType": "ASSUMPTION",
        "isSchemeRequired": false,
        "inheritedFromParentScheme": false,
        "cqStatusEnum": "PENDING_REVIEW",
        "challenged": false,
        "challengeCount": 0,
        "cqRequiresEvidence": false,
        "cqBurden": "PROPONENT",
        "answerSelfCanonical": true,
        "answerAuthorKind": "AI",
        "status": "pending_review"
      },
      {
        "cqKey": "PR.SIDE_EFFECTS",
        "text": "Do negative consequences of A outweigh achieving G?",
        "attackKind": "REBUTS",
        "cqStatusId": "cmr5cdnoy0015g1e29w47w2nk",
        "schemeKey": "practical_reasoning",
        "premiseType": "ASSUMPTION",
        "isSchemeRequired": false,
        "inheritedFromParentScheme": false,
        "cqStatusEnum": "PENDING_REVIEW",
        "challenged": false,
        "challengeCount": 0,
        "cqRequiresEvidence": false,
        "cqBurden": "PROPONENT",
        "answerSelfCanonical": true,
        "answerAuthorKind": "AI",
        "status": "pending_review"
      }
    ],
    "unanswered": []
  },
  "schemeInstance": null,
  "confidence": null,
  "dialecticalStatus": {
    "incomingAttacks": 2,
    "incomingSupports": 0,
    "incomingAttackEdges": 0,
    "criticalQuestionsRequired": 6,
    "criticalQuestionsAnswered": 0,
    "criticalQuestionsOpen": 6,
    "standingScore": 0.167,
    "isTested": false,
    "testedness": "lightly_tested",
    "standingState": "tested-undermined",
    "standingDepth": {
      "challengers": 0,
      "independentReviewers": 0,
      "lastChallengedAt": "2026-07-03T19:47:58.849Z",
      "lastDefendedAt": null,
      "confidence": "thin"
    },
    "fitnessBreakdown": {
      "total": -1.75,
      "components": {
        "cqAnswered": {
          "count": 0,
          "weight": 1,
          "contribution": 0
        },
        "supportEdges": {
          "count": 0,
          "weight": 0.5,
          "contribution": 0
        },
        "attackEdges": {
          "count": 0,
          "weight": -0.7,
          "contribution": 0
        },
        "attackCAs": {
          "count": 2,
          "weight": -1,
          "contribution": -2
        },
        "evidenceWithProvenance": {
          "count": 1,
          "weight": 0.25,
          "contribution": 0.25
        }
      },
      "weights": {
        "cqAnswered": 1,
        "supportEdges": 0.5,
        "attackEdges": -0.7,
        "attackCAs": -1,
        "evidenceWithProvenance": 0.25
      }
    }
  },
  "deliberation": {
    "id": "cmp6823ov00008cbr3jjscs6o",
    "title": "My Arguments"
  },
  "author": {
    "id": "mcp-bot",
    "displayName": "Isonomia MCP Bot",
    "kind": "AI",
    "aiProvenance": {
      "via": "mcp",
      "tool": "propose_structured_argument",
      "createdAt": "2026-07-03T19:42:22.115Z"
    }
  }
}